Type 1 diabetes: Medications

Early treatment with the anti-CD3 monoclonal antibody teplizumab may help to preserve β-cell function in children and adolescents with newly diagnosed type 1 diabetes, results of the phase 3 PROTECT study show.

Automated insulin delivery reduces hypoglycemia in people with type 1 diabetes at increased risk, improving their time spent in target glucose range.

Teplizumab consistently preserves the function of β-cells in people with type 1 diabetes as measured by higher C-peptide levels at 1 and 2 years post-treatment.

Results of a pilot study show that a hybrid closed-loop insulin delivery system customized for pregnancy used by women with type 1 diabetes at home significantly improved their glucose outcomes.

Pregnant women with type 1 diabetes can achieve similar glucose control regardless of whether they use insulin degludec or detemir, show the results of the randomised EXPECT trial.

Click through to read more on this announcement

People with type 1 diabetes who take GLP-1 receptor agonists or SGLT2 inhibitors in clinical practice have outcomes that are mostly – but not all – in line with those in controlled trials, say researchers.

Findings from a nationally representative US survey show that a substantial minority of people with diabetes ration their use of insulin because of issues with affordability.

Among adolescents with type 1 diabetes, those with better self-care are more likely to have favorable glycated hemoglobin trajectories into early adulthood, study findings suggest.

Delayed prandial insulin boluses are common in people using advanced technologies for the management of type 1 diabetes and are associated with adverse glycemic outcomes, suggest real-world study results.

A number of factors are associated with severe hypoglycemia risk in people with type 2 diabetes treated with insulin or sulfonylureas, suggests research reported at the 58th EASD Annual Meeting in Stockholm, Sweden.

Skin reactions to glucose monitors and insulin pumps occur in more than a quarter of users but only occasionally result in device discontinuation, research shows.

Findings from the phase 2 ARCADIA trial suggest that treatment with a glucokinase activator may aid the recovery of people with diabetes who are hospitalized with severe COVID-19.

People with type 1 diabetes who take a higher daily dose of insulin may have an increased risk for cancer compared with those on lower doses, US researchers report.

Starting people on bevacizumab and switching to aflibercept only when necessary keeps costs down without compromising treatment efficacy for people with diabetic macular edema, shows a randomized trial.

Use of the Tandem Control IQ hybrid closed-loop insulin delivery system improves time in range even for users who very rarely bolus for meals or to treat hyperglycemia, an observational study suggests.

Deintensifying diabetes treatment does not increase the risk for short-term adverse outcomes in male nursing home residents with limited life expectancy or advanced dementia, say researchers.

Switching 1% of standard bolus insulin lispro to a liver-targeted formulation decreases hypoglycemic events without affecting glucose control, OPTI-1 study findings indicate.

Ultra-rapid lispro gives equivalent overall glycemic control to standard lispro, and is significantly better for some postprandial measurements in children with type 1 diabetes, shows the PRONTO-Peds trial.

Adding daily empagliflozin to closed-loop insulin delivery improves time in range but also increases ketone levels in people with type 1 diabetes, shows a randomized trial.